Autosomal Recessive Polycystic Kidney Disease
📧 Sign up to get email alerts when something new happens for Autosomal Recessive Polycystic Kidney Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A Study to See Iftolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old withAutosomal Recessive Polycystic Kidney Disease (ARPKD) [Phase 3]
Phase 3 clinical trial to evaluate the safety of Iftolvaptan in infants and children aged 28 days to under 18 years with autosomal recessive…
-
CLINICAL_TRIALS withdrawal · 2025-12-24Clinical Trial Update: A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD) [Phase 3]
A Phase 3 study evaluating tolvaptan to delay dialysis in infants and young children with autosomal recessive polycystic kidney disease has …
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: Imaging Assessments of ARPKD Kidney Disease Progression
This clinical trial update notes imaging-based assessments to monitor progression of autosomal recessive polycystic kidney disease (ARPKD) a…
-
CLINICAL_TRIALS research · 2025-06-13Clinical Trial Update: ARPKD Database Study
ClinicalTrials.gov entry indicates that the ARPKD Database Study sponsored by Children’s Hospital of Philadelphia is currently recruiting, a…
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: Congenital Hepatic Fibrosis and Autosomal Recessive Polycystic Kidney Disease in Children at Sohag University Hospital
This ClinicalTrials.gov entry describes a recruiting study at Sohag University Hospital investigating congenital hepatic fibrosis and autoso…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.